SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001178913-23-003460
Filing Date
2023-10-31
Accepted
2023-10-31 07:05:10
Documents
1
Group Members
I.B.F MANAGEMENT LTD.ISRAEL BIOTECH FUND GP PARTNERS II, L.P.ISRAEL BIOTECH FUND GP PARTNERS, L.P.ISRAEL BIOTECH FUND II, L.P.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A zk2330451.htm SC 13D/A 213147
  Complete submission text file 0001178913-23-003460.txt   215039
Mailing Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852
Business Address 9 DEER PARK DRIVE SUITE K-1 MONMOUTH JUNCTION NJ 08852 732 545 1590
Ayala Pharmaceuticals, Inc. (Subject) CIK: 0001100397 (see all company filings)

IRS No.: 841521955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-80101 | Film No.: 231362248
SIC: 2834 Pharmaceutical Preparations

Mailing Address 4 OPPENHEIMER ST. REHOVOT L3 7670104
Business Address 4 OPPENHEIMER ST. REHOVOT L3 7670104 972-722-514-175
Israel Biotech Fund I, L.P. (Filed by) CIK: 0001652458 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A